Losartan inhibits LPS-induced inflammatory signaling through a PPARγ-dependent mechanism in human THP-1 macrophages

Hypertension Research

Volumn 33, Issue 8, 2010, Pages 831-835

  An, Jianbo ^a   Nakajima, Toshiaki ^a   Kuba, Keiji ^a,b   Kimura, Akinori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

inflammatory cytokine; losartan; LPS; macrophage; PPAR

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BACTERIUM LIPOPOLYSACCHARIDE; CYCLOOXYGENASE 2; I KAPPA B; INTERLEUKIN 8; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE; COMPETITIVE INHIBITION; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; INTRACELLULAR SIGNALING; MACROPHAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSINOGEN; ATHEROSCLEROSIS; CELL LINE; GENE EXPRESSION; HUMANS; HYPERTENSION; I-KAPPA B PROTEINS; INFLAMMATION; LIPOPOLYSACCHARIDES; LOSARTAN; MACROPHAGES; MONOCYTES; PHOSPHORYLATION; PPAR GAMMA; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 77955358792     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.79     Document Type: Article

References (27)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Bräsen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Böhm M, Meinertz T, Münzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99: 2027-2033.
3. Toko H, Zou Y, Minamino T, Masaya M, Harada M, Nagai T, Sugaya T, Terasaki F, Kitaura Y, Komuro I. Angiotensin II type 1a receptor is involved in cell infiltration, cytokine production, and neovascularization in infarcted myocardium. Arterioscler Thromb Vasc Biol 2004; 24: 664-670.
4. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82-C97.
5. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-1161.
6. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-3108.
7. Shinohara M, Hirata K, Yamashita T, Takaya T, Sasaki N, Shiraki R, Ueyama T, Emoto N, Inoue N, Yokoyama M, Kawashima S. Local overexpression of toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR2 and TLR4. Arterioscler Thromb Vasc Biol 2007; 27: 2384-2391.
8. Kawai T, Akira S. TLR signaling. Semin Immunol 2007; 19: 24-32.
9. Ji Y, Liu J, Wang Z, Liu N. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 2009; 23: 265-276.
10. Lund DD, Brooks RM, Faraci FM, Heistad DD. Role of angiotensin II in endothelial dysfunction induced by lipopolysaccharide in mice. Am J Physiol Heart Circ Physiol 2007; 293: H3726-H3731.
11. Sanchez-Lemus E, Murakami Y, Larrayoz-Roldan IM, Moughamian AJ, Pavel J, Nishioku T, Saavedra JM. Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland. Endocrinology 2008; 149: 5177-5188.
12. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109: 2054-2057.
13. Larrayoz IM, Pang T, Benicky J, Pavel J, Sánchez-Lemus E, Saavedra JM. Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes. J Hypertens 2009; 27: 2365-2376.
14. Chen S, Ge Y, Si J, Rifai A, Dworkin LD, Gong R. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int 2008; 74: 1128-1138.
15. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, Garg R. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003; 88: 4496-4501.
16. Yamashita C, Hayashi T, Mori T, Tazawa N, Kwak CJ, Nakano D, Sohmiya K, Okada Y, Kitaura Y, Matsumura Y. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 2007; 30: 1219-1230.
17. Krämer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, Tsikas D, Böger RH, Forssmann WG, Drexler H, Schieffer B. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002; 90: 770-776.
18. Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T, Kintscher U. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 2006; 47: 586-589.
19. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
20. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
21. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
22. Hodges VM, Molloy GY, Wickramasinghe SN. Demonstration of mRNA for five species of cytochrome P450 in human bone marrow, bone marrow-derived macrophages and human haemopoietic cell lines. Br J Haematol 2000; 108: 151-156.
23. Sieben S, Baron JM, Blömeke B, Merk HF. Multiple cytochrome P450-isoenzymes mRNA are expressed in dendritic cells. Int Arch Allergy Immunol 1999; 118: 358-361.
24. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48-52.
25. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, Hoffmann A, Subramaniam S, David M, Rosenfeld MG, Glass CK. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005; 122: 707-721.
26. Moon Y, Yang H, Park SH. Hypo-responsiveness of interleukin-8 production in human embryonic epithelial intestine 407 cells independent of NF-kappaB pathway: new lessons from endotoxin and ribotoxic deoxynivalenol. Toxicol Appl Pharmacol 2008; 231: 94-102.
27. Sadoshima J. Novel AT1 receptor-independent functions of losartan. Circ Res 2002; 90: 754-756.